Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10
Indian (NIFTY) Pharma Industry Analysis
UpdatedApr 22, 2024
DataAggregated Company Financials
Companies159
- 7D-1.4%
- 3M6.1%
- 1Y53.7%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 1.4%, driven by declines in Sun Pharma Advanced Research and Cipla of 19% and 1.9%, respectively. This takes the industry's 12 month performance to a gain of 54%. Looking forward, earnings are forecast to grow by 19% annually.
Industry Valuation and Performance
Has the Indian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 22 Apr 2024 | ₹16.6t | ₹3.5t | ₹418.9b | 33.2x | 39.6x | 4.8x |
| Wed, 20 Mar 2024 | ₹16.4t | ₹3.5t | ₹418.7b | 32.1x | 39.2x | 4.7x |
| Fri, 16 Feb 2024 | ₹16.7t | ₹3.5t | ₹427.8b | 33.6x | 39x | 4.8x |
| Sun, 14 Jan 2024 | ₹15.7t | ₹3.4t | ₹395.3b | 35.2x | 39.6x | 4.6x |
| Tue, 12 Dec 2023 | ₹14.2t | ₹3.4t | ₹395.1b | 31.8x | 35.9x | 4.2x |
| Thu, 09 Nov 2023 | ₹13.6t | ₹3.3t | ₹382.3b | 30.7x | 35.6x | 4.1x |
| Sat, 07 Oct 2023 | ₹13.1t | ₹3.3t | ₹369.9b | 30.1x | 35.4x | 4x |
| Mon, 04 Sep 2023 | ₹12.8t | ₹3.3t | ₹367.0b | 29.3x | 34.9x | 3.9x |
| Wed, 02 Aug 2023 | ₹12.8t | ₹3.2t | ₹345.9b | 29.6x | 37x | 4x |
| Fri, 30 Jun 2023 | ₹11.7t | ₹3.2t | ₹342.4b | 26.6x | 34x | 3.7x |
| Sun, 28 May 2023 | ₹10.6t | ₹3.1t | ₹339.1b | 27.3x | 31.1x | 3.4x |
| Tue, 25 Apr 2023 | ₹9.9t | ₹3.0t | ₹277.7b | 25.9x | 35.6x | 3.3x |
| Thu, 23 Mar 2023 | ₹9.4t | ₹3.0t | ₹277.5b | 23.9x | 33.9x | 3.1x |
| Sat, 18 Feb 2023 | ₹9.6t | ₹3.0t | ₹277.5b | 23.6x | 34.7x | 3.2x |
| Mon, 16 Jan 2023 | ₹9.9t | ₹2.9t | ₹275.2b | 26x | 36.2x | 3.4x |
| Wed, 14 Dec 2022 | ₹10.0t | ₹2.9t | ₹274.9b | 26.6x | 36.5x | 3.5x |
| Fri, 11 Nov 2022 | ₹10.1t | ₹2.8t | ₹261.9b | 25x | 38.8x | 3.6x |
| Sun, 09 Oct 2022 | ₹10.0t | ₹2.8t | ₹260.4b | 24.2x | 38.4x | 3.6x |
| Tue, 06 Sep 2022 | ₹9.7t | ₹2.8t | ₹262.0b | 24.1x | 37x | 3.5x |
| Thu, 04 Aug 2022 | ₹9.7t | ₹2.8t | ₹284.5b | 22x | 34x | 3.5x |
| Sat, 02 Jul 2022 | ₹9.3t | ₹2.8t | ₹274.6b | 21x | 34x | 3.4x |
| Mon, 30 May 2022 | ₹9.6t | ₹2.7t | ₹312.4b | 20.7x | 30.7x | 3.5x |
| Wed, 27 Apr 2022 | ₹10.0t | ₹2.7t | ₹338.0b | 24.1x | 29.5x | 3.7x |
| Fri, 25 Mar 2022 | ₹10.1t | ₹2.7t | ₹337.9b | 24.3x | 29.9x | 3.7x |
| Sun, 20 Feb 2022 | ₹9.8t | ₹2.7t | ₹338.2b | 23x | 28.9x | 3.6x |
| Tue, 18 Jan 2022 | ₹10.6t | ₹2.7t | ₹361.8b | 26.2x | 29.2x | 4x |
| Thu, 16 Dec 2021 | ₹10.2t | ₹2.7t | ₹360.6b | 24.1x | 28.4x | 3.9x |
| Sat, 13 Nov 2021 | ₹10.4t | ₹2.6t | ₹362.1b | 22.3x | 28.6x | 3.9x |
| Mon, 11 Oct 2021 | ₹10.9t | ₹2.6t | ₹376.2b | 25.8x | 29.1x | 4.2x |
| Wed, 08 Sep 2021 | ₹10.9t | ₹2.6t | ₹374.6b | 25x | 29x | 4.2x |
| Fri, 06 Aug 2021 | ₹11.1t | ₹2.6t | ₹375.2b | 25.4x | 29.6x | 4.3x |
| Mon, 10 May 2021 | ₹9.9t | ₹2.5t | ₹332.3b | 20.5x | 29.8x | 4x |
Price to Earnings Ratio
29.8x
Current Industry PE
- Investors are optimistic on the Indian Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 39.6x which is higher than its 3-year average PE of 33.6x.
- The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.8x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 8.0% per year over the last three years.
- Revenues for these companies have grown 12% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Indian Pharma compare with similar industries?
| IN Market | -1.57% | |
| Healthcare | -1.97% | |
| Pharma | -1.41% | |
| Pharma | -1.41% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MANKIND Mankind Pharma | ₹2.34k | 3.2% +₹29.3b | n/a | PE54.3x | |
| ZYDUSLIFE Zydus Lifesciences | ₹959.70 | 2.6% +₹24.7b | 85.6% | PE32.7x | |
| 500420 Torrent Pharmaceuticals | ₹2.59k | 2.8% +₹24.1b | 59.8% | PE58.7x | |
| 500660 GlaxoSmithKline Pharmaceuticals | ₹1.95k | 2.4% +₹7.7b | 55.4% | PE62.4x | |
| 524558 Neuland Laboratories | ₹7.63k | 7.3% +₹6.7b | 284.3% | PE30.9x |